Sweden has chosen a protein-based COVID vaccine as the only one for its national program in the 2027/2028 season. This is the first time a country has done so for a full national campaign. Officials point to familiar technology and practical handling. Critics of the mRNA shots used since 2021 see a larger meaning. The records show a clear procurement change, not a ban. Readers can weigh both sides from the primary sources.
What Sweden Actually Decided
In April 2026, Sanofi announced that its protein-based vaccine Nuvaxovid had won Sweden’s national tender for COVID-19 vaccines for people aged 12 and older for the 2027/2028 season. The tender was run by Adda Inköpscentral on behalf of all 21 regions. It was the first time Sweden ran its own national COVID vaccine procurement instead of relying on the earlier European Union pandemic contracts. Sanofi stated that Sweden is the first country in the world to procure only a protein-based COVID vaccine for a national seasonal campaign. Sanofi press release, 21 April 2026
The contract covers the period from 1 June 2027 to 31 August 2028. Nuvaxovid is supplied in pre-filled syringes that can be stored in a regular refrigerator. Adda’s public page confirms Sanofi as the accepted supplier for adults and adolescents from age 12. No bids came in for children under 12, so that part of the tender stayed empty. Adda procurement page
From 1 January 2027 the responsibility for supplying COVID vaccines shifts from the national level to the regions. The Swedish government has instructed the Public Health Agency to sell surplus doses to the regions during the transition so that nothing is wasted. This is a logistics and budget matter, separate from the choice of which vaccine type was selected for the later season.
How the Two Technologies Differ
Nuvaxovid is a protein subunit vaccine. It contains a ready-made piece of the virus—the spike protein—made by recombinant methods and paired with an adjuvant that helps the immune system respond. The same basic approach has been used for years in vaccines against hepatitis B and human papillomavirus. The body receives a fixed amount of the antigen. It does not receive genetic instructions to produce the protein itself.
URGENT: Sweden will not offer mRNA-based Covid shots to its citizens this winter, only older protein-based jabs - a stunning rejection. Expect other countries to follow as we learn more about the long-term risks of repeated mRNA/LNP dosing. https://t.co/sZZIYpmccF
— Alex Berenson (@AlexBerenson) October 27, 2026
mRNA vaccines, by contrast, deliver messenger RNA wrapped in lipid nanoparticles. The mRNA enters some of the person’s cells and tells those cells to manufacture the spike protein for a limited time. The immune system then reacts to that self-produced protein. Official product information and public-health summaries note that the amount and duration of spike production are not measured in the same way as a fixed protein dose. Lipid nanoparticles can move beyond the injection site. These points are the main technical differences that alternative health voices have highlighted for years.
Both approaches aim to train the immune system against the spike. Official agencies continue to describe mRNA products as effective against severe disease. The Swedish Public Health Agency still lists Comirnaty (the Pfizer-BioNTech mRNA vaccine) as the main product in use today. Nuvaxovid itself has also been linked to rare reports of heart-muscle and heart-sac inflammation, the same signals that led to age restrictions on mRNA shots in several Nordic countries in 2021.
Official Reasons for the Choice
Sanofi and Swedish medical media describe the decision as a move to “well-known and proven” technology. Lena Svensson, medical lead at Sanofi Vaccines in Sweden, said the choice marks an important step in treating COVID-19 as a recurring seasonal infection and that the pre-filled syringe and refrigerator storage make the work easier for the regions. Professor Niklas Arnberg of Umeå University welcomed the broader vaccine choice, noting that infection can still lead to post-COVID conditions and higher risks of heart and vessel problems.
COVID-19 still causes deaths and intensive-care admissions in Sweden, though at far lower levels than in 2020–2021. The Public Health Agency recommends an annual dose, mainly in autumn, for people over 75, certain risk groups from age 50, and people with weakened immune systems. Coverage among those over 75 has been reported around 73 percent. The procurement decision was framed around disease burden, logistics, and the fact that Sweden was running its own tender for the first time.
There is no public statement from Swedish authorities that the choice was driven by safety concerns about mRNA products. The competing bids came from Pfizer in Sweden and Moderna Netherlands. Sanofi won on the evaluation criteria used by Adda. The price is not published.
The Earlier Advice Against Nuvaxovid for Younger People
In November 2022 the Public Health Agency advised against using Nuvaxovid in people under 30 because of a possible higher risk of myocarditis and pericarditis. That advice is still listed on the agency’s website as of late 2026. Ulrika Marking, an investigator at the agency, told LäkemedelsVärlden in June 2026 that the agency had already told regional infectious-disease doctors it planned to lift the age restriction. She said the original suspicion of myocarditis “is not at all current in the same way any longer” and that the recommendation will be changed in good time before the autumn 2027 season, when the new procurement vaccine would be used widely. LäkemedelsVärlden, 5 June 2026
Sweden is officially ditching mRNA vaccines, and they are not hiding their reasons for doing so. https://t.co/qQzN68nhWA https://t.co/GOMJgbSGri
— Mazda Sabouri (@msabouri) October 26, 2026
This detail is rarely mentioned in the short social-media versions of the story. The same vaccine that alternative outlets celebrate as the exit from mRNA once carried an age warning of its own. Officials now say the earlier signal no longer holds with the same strength. Readers who want the full context can compare the 2022 advice with the 2026 statements.
Sweden’s Pattern of Independent Choices
During the pandemic Sweden did not impose the same lockdowns or school closures used in many other countries. The Public Health Agency argued that voluntary measures and focused protection of the vulnerable were enough. That choice drew sharp criticism at the time. Later commentary in some European media was more mixed. The 2027 vaccine procurement continues the same pattern: Sweden ran its own tender once the old EU contracts were no longer the default and selected the product that met its criteria.
Whether the earlier pandemic path was wise remains debated. Excess-death figures, school outcomes, and hospital load have all been examined in multiple studies with different conclusions. The vaccine decision is narrower. It is a procurement outcome for one season’s national campaign, not a repeal of marketing authorizations.
What Alternative Voices Emphasize
Groups that have long questioned mRNA technology describe the Swedish choice as a vindication. They point to the fixed antigen dose in protein vaccines, the limited systemic spread of lipid nanoparticles, and the years of adverse-event reports collected for the mRNA products. A Dutch doctors’ collective published a piece on 23 October 2026 that framed the move as Sweden becoming the first country to leave Pfizer and Moderna mRNA vaccines behind for its national campaign. The piece notes Sweden’s earlier independent pandemic path and calls the new procurement a further step. Artsen Collectief, 23 October 2026
Similar framing has appeared in other alternative outlets and on social media. Some posts say Sweden has “abandoned” or “banned” mRNA. Primary documents do not use those words. mRNA vaccines remain authorized in Sweden. They can still be obtained outside the national campaign supply for the 2027/28 season if a clinician and patient choose them. The national program itself, however, will offer Nuvaxovid as the procured product for the recommended groups.
Readers who follow longer debates on excess mortality, cardiac signals, and regulatory handling of the mRNA products can compare the Swedish procurement with other recent coverage. One related examination of those wider questions appears on this site: The COVID Reckoning That Never Came: Excess Deaths, mRNA Shots, and Official Silence in 2026.
What the Change Does Not Mean
Sweden has not withdrawn marketing authorization for Comirnaty or other mRNA COVID vaccines. The Public Health Agency continues to describe the mRNA product in current use as effective against severe disease. Nuvaxovid is not available in Sweden at the moment; the new supply arrives with the 2027 contract. The shift applies to the doses the regions will buy and distribute under the national campaign for the 2027/28 season. It does not prevent private or clinical use of other authorized vaccines if they remain on the market.
The decision also does not settle the larger scientific arguments about lipid nanoparticles, spike-protein persistence, or long-term all-cause mortality signals. Those debates continue in medical journals, regulatory filings, and public commentary. Official risk-benefit statements still hold that benefits outweigh risks for the groups currently recommended for vaccination. Alternative analyses reach different conclusions on the same data sets. The Swedish procurement is one country’s practical choice for one future season, made after competitive bidding.
Looking at the Primary Records
Anyone who wants to check the claims can read the original documents. The Sanofi announcement of 21 April 2026 is the clearest commercial statement. Adda’s page lists the contract terms and the accepted product. The June 2026 article in LäkemedelsVärlden records the Public Health Agency’s plan to revise the earlier age advice. The agency’s own vaccination page still describes both mRNA and protein options and notes the current age guidance for Nuvaxovid. These sources are public. They do not require interpretation through secondary headlines.
Sweden’s choice is real. It is limited in scope. It favors a protein platform for the next national seasonal campaign. Whether that platform proves simpler, safer, or equally effective in practice will be measured after the doses are used in 2027 and 2028. Both the official framing and the critical reading can be tested against the same primary records.
Original source and date: Sanofi press release, 21 April 2026, and subsequent Swedish medical reporting; alternative framing in Artsen Collectief, 23 October 2026. Full primary links appear above.
Disclaimer for fact-checkers: This article draws on official Swedish procurement announcements, Public Health Agency statements, and alternative health commentary. Official sources describe a procurement decision favoring known technology and logistics. Alternative sources interpret the same decision as a rejection of mRNA platforms. Primary documents are linked so readers can compare the wording directly. No claim of a full ban or withdrawal of authorization is supported by the official records.